PMID- 36548687
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221227
IS  - 2414-6366 (Electronic)
IS  - 2414-6366 (Linking)
VI  - 7
IP  - 12
DP  - 2022 Dec 12
TI  - Clinical-Epidemiological Characteristics and Outcomes of Latent Tuberculosis 
      Treatment at a Tertiary Center in Central-West Brazil from 2017 to 2019.
LID - 10.3390/tropicalmed7120432 [doi]
LID - 432
AB  - Detailed information concerning latent tuberculosis infection (LTBI) and 
      treatment outcomes is scarce in Brazil. This retrospective cross-sectional study 
      aimed to describe LTB treatment (LTBT) at a tertiary center in Central-West 
      Brazil from 2017 to 2019. We recommended the use of LTBTs before the 
      implementation of a rifapentine-isoniazid (3HP) regimen in Brazil. We conducted a 
      descriptive analysis using chi-square or t-tests to assess differences in the 
      proportions and means. Of 79 notified adult patients (males, 68%; median age, 40 
      (interquartile range, 30-51) years), most people were living with human 
      immunodeficiency virus (PLHIV) (82%) or receiving immunosuppressant medication 
      (15%), and 92% were receiving their first treatment. Isoniazid (INH) for 6-9 
      months had previously been proposed for 95% of the patients, with only 35% 
      completeness. Four patients treated with rifampicin (4RMP) completed the regimen 
      (p = 0.009). Adverse events occurred in 19% of the patients. In this Brazilian 
      tertiary center, the target population for LTBT were young PLHIV patients under 
      immunosuppression with low education levels. However, the INH monotherapy dropout 
      rate was 65%. Therefore, shorter courses, such as 3HP and 4RMP, are promising 
      alternatives. Behavioral aspects, education level, and regimen length can 
      influence the course completion, and further studies are required to evaluate the 
      3HP regime in Brazil.
FAU - Borges, Moara Alves Santa Barbara
AU  - Borges MASB
AUID- ORCID: 0000-0003-2461-2063
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias, 
      Goiania 74605-050, Brazil.
AD  - Clinical Hospital, Federal University of Goias, Empresa Brasileira de Servicos 
      Hospitalares, Goiania 74605-050, Brazil.
FAU - Cunha, Iago Dib
AU  - Cunha ID
AD  - Medicine School, Federal University of Goias, Goiania 74605-050, Brazil.
FAU - Candini, Luis Henrique
AU  - Candini LH
AD  - Medicine School, Federal University of Goias, Goiania 74605-050, Brazil.
FAU - de Souza, Vitor Alves
AU  - de Souza VA
AD  - Medicine School, Federal University of Goias, Goiania 74605-050, Brazil.
FAU - da Costa, Paulo Sergio Sucasas
AU  - da Costa PSS
AUID- ORCID: 0000-0001-9370-9139
AD  - Medicine School, Federal University of Goias, Goiania 74605-050, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20221212
PL  - Switzerland
TA  - Trop Med Infect Dis
JT  - Tropical medicine and infectious disease
JID - 101709042
PMC - PMC9787027
OTO - NOTNLM
OT  - HIV
OT  - anti-tuberculosis agent
OT  - epidemiology
OT  - latent tuberculosis infections
OT  - therapies
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/23 06:00
MHDA- 2022/12/23 06:01
PMCR- 2022/12/12
CRDT- 2022/12/22 15:13
PHST- 2022/10/13 00:00 [received]
PHST- 2022/11/26 00:00 [revised]
PHST- 2022/12/07 00:00 [accepted]
PHST- 2022/12/22 15:13 [entrez]
PHST- 2022/12/23 06:00 [pubmed]
PHST- 2022/12/23 06:01 [medline]
PHST- 2022/12/12 00:00 [pmc-release]
AID - tropicalmed7120432 [pii]
AID - tropicalmed-07-00432 [pii]
AID - 10.3390/tropicalmed7120432 [doi]
PST - epublish
SO  - Trop Med Infect Dis. 2022 Dec 12;7(12):432. doi: 10.3390/tropicalmed7120432.